Naltrexone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Naltrexone: From Opioid/Alcohol Use Disorder to Hypervitaminosis
One-Sentence Summary
Naltrexone is a mu-opioid receptor antagonist internationally used for opioid and alcohol use disorder; no Australia-specific approved indication is on file since the drug is not currently registered here. The TxGNN model predicts possible activity in Hypervitaminosis, but this candidate currently has no supporting clinical trials and no supporting literature, and a blocking safety data gap remains unresolved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file for Australia (drug not registered locally); internationally used for opioid/alcohol use disorder |
| Predicted New Indication | Hypervitaminosis |
| TxGNN Prediction Score | 98.66% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (data gap DG002, High severity). Naltrexone is widely known as a mu-opioid receptor antagonist, used internationally to treat opioid dependence and alcohol use disorder — this is general pharmacological knowledge, not confirmed via Australian regulatory sources here, since naltrexone has no ARTG entries.
The predicted new indication, hypervitaminosis (vitamin excess/toxicity), has no obvious pharmacological or clinical relationship to opioid receptor antagonism. The TxGNN score (98.66%, ranked 13,245 out of all drug–disease pairs in the model) reflects a statistical association from the model’s knowledge-graph embeddings rather than a validated biological mechanism.
No clinical trials or published literature currently support a naltrexone–hypervitaminosis link. This is a pure model-generated hypothesis (Evidence Level L5) and should be treated as exploratory only until independent mechanistic or clinical evidence emerges.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Australia Market Information
Naltrexone is not currently registered on the ARTG (0 entries) — no Australian market information is available.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- A blocking data gap (DG001) means no TFDA/TGA-equivalent product information — warnings or contraindications — is available, so safety cannot be assessed.
- The top predicted indication, hypervitaminosis, has zero clinical trial or literature support (Evidence Level L5, model prediction only).
- Naltrexone is not currently registered in Australia (0 ARTG entries), so there is no local regulatory pathway or safety record to build on.
To proceed, the following is needed:
- TGA-equivalent Product Information: warnings, precautions, and contraindications (currently Blocking gap DG001)
- Confirmed mechanism of action data (DG002, High severity)
- A targeted literature/mechanistic search specifically testing naltrexone in hypervitaminosis, as none currently exists
- Consideration of other, more biologically plausible candidates in this batch — e.g., rank 5 “restless legs syndrome” (score 92.2%) returned 5 literature hits, though none directly evidence a naltrexone–RLS relationship and would need dedicated review before advancing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.